[Test] Tuberculosis Manual Acronym Dictionary
| Abbreviation | Definition |
|---|---|
| 3HP | 3 months isoniazid + rifapentine (once weekly) |
| 4RIF | 4 months rifampin (daily) |
| 6INH | 6 months isoniazid (daily) |
| 9INH | 9 months isoniazid (daily) |
| AAP | American Academy of Pediatrics |
| ACET | Advisory Council for the Elimination of Tuberculosis |
| ACH | air changes per hour |
| AFB | acid-fast bacilli |
| AIDS | acquired immunodeficiency syndrome |
| AK | amikacin |
| AII | airborne infection isolation |
| ALT | alanine aminotransferase |
| ARPE | Aggregate Report for Program Evaluation |
| ART | antiretroviral therapy |
| AST | aspartate aminotransferase |
| ATS | American Thoracic Society |
| BAMT | blood assay for Mycobacterium tuberculosis |
| BCG | Bacille Calmette-Guerin |
| CAP | capreomycin |
| CDC | Centers for Disease Control and Prevention |
| CIS | ciprofloxacin |
| CIS | cycloserine |
| CT | computed tomography |
| CXR | chest radiograph |
| DNA | deoxyribonucleic acid |
| DOT | directly observed therapy |
| DPS | Department of Public Safety |
| DS Form | Department of State Form |
| DTBE | Division of Tuberculosis Elimination |
| DTH | delayed-type hypersensitivity |
| ED | emergency department |
| EMB | ethambutol |
| EMS | emergency medical service |
| ESRD | end-stage renal disease |
| FDA | U.S. Food and Drug Administration |
| HAART | highly active antiretroviral therapy |
| HCW | healthcare worker |
| HCP | health care personnel |
| HEPA | high-efficiency particulate air |
| HIPAA | Health Insurance Portability and Accountability Act |
| HIV | human immunodeficiency virus |
| HLV | Health Law Violator |
| IDSA | Infectious Diseases Society of America |
| IGRA | interferon gamma release assay |
| INH | isoniazid |
| KM | kanamycin |
| LHD | Local Health Department |
| LTBI | latent tuberculosis infection |
| M. tuberculosis | Mycobacterium tuberculosis |
| MDR-TB | multidrug-resistant tuberculosis |
| MIRU | mycobacterial interspersed repetitive units |
| MMWR | Morbidity and Mortality Weekly Report |
| MOTT | mycobacterium other than tuberculosis |
| MXF | moxifloxacin |
| NAAT | nucleic acid amplification Test |
| NCEDSS | North Carolina Electronic Disease Surveillance System |
| NIOSH | National Institute for Occupational Safety and Health |
| NNRTI | nonnucleoside reverse transcriptase inhibitors |
| NTCA | National Tuberculosis Controllers Association |
| NTM | nontuberculous mycobacteria |
| NTNC | National Tuberculosis Nurse Coalition |
| OSHA | Occupational Safety and Health Administration |
| PAPR | powered air-purifying respirator |
| PCR | polymerase chain reaction |
| PA | Posterior-Anterior |
| PAS | Para-aminosalicylic acid |
| PAPR | Powered air purifying respirator |
| PI | protease inhibitor |
| PHN | Public Health Nurse |
| PMD | private medical doctor |
| PPD | purified protein derivative |
| PPE | personal protective equipment |
| PZA | pyrazinamide |
| QA | quality assurance |
| QFT | QuantiFERON-TB test |
| QFT-G IT | QuantiFERON-TB Gold In-tube |
| RFB | rifabutin |
| RFLP | restriction fragment length polymorphism |
| RIF | rifampin |
| RIPE | Standard TB Treatment with rifampin, isoniazid, pyrazinamide, ethambutol. |
| RNA | ribonucleic acid |
| RPT | rifapentine |
| RVCT | Report of Verified Case of Tuberculosis |
| RZ | rifampin and pyrazinamide |
| SM | streptomycin |
| TB | tuberculosis |
| THA | ethionamide |
| TIMS | Tuberculosis Information Management System |
| TNF-? | tumor necrosis factor-alpha |
| TLTBI | treatment of latent TB infection |
| TST | tuberculin skin test |
| TU | tuberculin units |
| USCIS | U.S. Citizenship and Immigration Services |
| UVGI | ultraviolet germicidal irradiation |
| XDR-TB | extremely drug-resistant tuberculosis |
100
true
Narrow